<DOC>
	<DOC>NCT00705861</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of SK3530 on erectile dysfunction in Patients with Diabetes Mellitus.</brief_summary>
	<brief_title>Study to Assess the Efficacy and Safety of SK3530 on Erectile Dysfunction in Patients With Diabetes Mellitus</brief_title>
	<detailed_description>SK3530 is a potent and selective phosphdiesterase type 5(PDE 5) inhibitor developed for the treatment of erectile dysfunction(ED). Since ED is common in men with Diabetes Mellitus, it is important to determine the efficacy and safety of SK3530 on erectile dysfunction in Patients with Diabetes Mellitus.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>clinical diagnosis of type 1 or type 2 diabetes. Score below 25 from IIEF EF domain during 4 weeks of treatment runin period. Failure rate above 50% from sexual attempt above 4 during 4 weeks of treatment runin period. Lab abnormality. Uncontrolled diabetic mellitus(HbA1c &gt; 12%). High or low blood pressure, orthostatic hypotension. Hyper or hypothyroidism.</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Erectile dysfunction</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>SK3530</keyword>
</DOC>